Management of statin-intolerant high-risk patients

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 632-637

  Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^b   Karagiannis, Asterios ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Colesevelam; Combination treatment; Creatine kinase; Ezetimibe; Fibrates; Myalgia; Nicotinic acid; Statins; Transaminase

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CYTOCHROME P450 3A4; DILTIAZEM; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL; ANTIOXIDANT; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; UBIDECARENONE; UBIQUINONE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLUSHING; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; MYOPATHY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; BLOOD; DIET SUPPLEMENTATION; DRUG COMBINATION; DRUG MONITORING; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; VASCULAR DISEASE;

ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; RISK FACTORS; UBIQUINONE; VASCULAR DISEASES;

EID: 74549156197     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792006932     Document Type: Article

References (119)

1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines forsecondary prevention for patients with coronary and other atheroscleroticvascular disease: 2006 update: endorsed by the NationalHeart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72.
2. Third Report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III) finalreport. Circulation 2002; 106: 3143-421.
3. Kashani A, Phillips CO, Foody JM, et al. Risks associated withstatin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-97.
4. Banach M, Mikhailidis DP, Ugurlucan M, et al. The significance ofstatin use in patients subjected to surgical coronary revascularization. Arch Med Sci 2007; 3: S126-S132.
5. Dembowski E, Davidson MH. Role of statin therapy in the managementof patients with the metabolic syndrome. Arch Med Sci 2007; 3: S102-S108.
6. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderlypatients. JAMA 2002; 288: 455-61.
7. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impactof concurrent medication use on statin adherence and refillpersistence. Arch Intern Med 2004; 164: 2343-8.
8. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapyin elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-7.
9. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuationof lipid modifying drugs among commercially insured UnitedStates patients in recent clinical practice. Am J Cardiol 2007; 99:530-4.
10. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of aprescription copayment increase on lipid-lowering medication adherencein veterans. Circulation 2009; 119: 390-7.
11. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients withand without acute myocardial infarction: a population-based naturalexperiment. Circulation 2007; 115: 2128-35.
12. Chan J, Hui RL, Levin E. Differential association between statinexposure and elevated levels of creatine kinase. Ann Pharmacother2005; 39: 1611-6.
13. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalizedrhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90.
14. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininducedmyopathy--a genomewide study. N Engl J Med 2008; 359:789-99.
15. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on theUse and Safety of Statins. Circulation 2002; 106: 1024-8.
16. Koskinas K, Tzellos TG, Gougoulias K, Gougoulias G, Papakonstantinou C, Kouvelas D. Simvastatin-induced rhabdomyolysis: acase study on clinical-decision making based on the evidence-basedmedicine approach. Arch Med Sci 2007; 3: 267-71.
17. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. adelayed conservative simvastatin strategy in patients with acutecoronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307-16.
18. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatinvs. usual-dose simvastatin for secondary prevention aftermyocardial infarction: the IDEAL study: a randomized controlledtrial. JAMA 2005; 294: 2437-45.
19. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid loweringwith atorvastatin in patients with stable coronary disease. N Engl JMed 2005; 352: 1425-35.
20. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety ofcholesterol-lowering treatment: prospective meta-analysis of datafrom 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
21. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA.Evaluation of cases of severe statin-related transaminitis within alarge health maintenance organization. Am J Med 2005; 118: 618-24.
22. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase andcreatine kinase measurements in a primary care setting. Arch InternMed 2003; 163: 688-92.
23. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of themagnitude of lipid lowering on risk of elevated liver enzymes,rhabdomyolysis, and cancer: insights from large randomized statintrials. J Am Coll Cardiol 2007; 50: 409-18.
24. Josan K, Majumdar SR, McAlister FA. The efficacy and safety ofintensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008; 178: 576-84.
25. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparativesafety of atorvastatin 80 mg vs. 10 mg derived from analysis of 49completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61-7.
26. Harper CR, Jacobson TA. The broad spectrum of statin myopathy:from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18: 401-8.
27. Jacobson TA. Toward pain-free statin prescribing: clinical algorithmfor diagnosis and management of myalgia. Mayo Clin Proc2008; 83: 687-700.
28. Law M, Rudnicka AR. Statin safety: a systematic review. Am JCardiol 2006; 97: 52C-60C.
29. Rosenson RS. Current overview of statin-induced myopathy. Am JMed 2004; 116: 408-16.
30. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathywith statin therapy in high-risk patients. Arch Intern Med 2003;163: 553-64.
31. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed followingstatin treatment. Arch Intern Med 2006; 166: 1519-24.
32. Weimer LH, Sachdev N. Update on medication-induced peripheralneuropathy. Curr Neurol Neurosci Rep 2009; 9: 69-75.
33. Bifulco M, Malfitano AM, Marasco G. Potential therapeutic role ofstatins in neurological disorders. Expert Rev Neurother 2008; 8:827-37.
34. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in45 patients with statin-associated myopathy. Arch Intern Med 2005; 165: 2671-6.
35. Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion toatorvastatin in patients intolerant or refractory to simvastatin therapy:the CAPISH study. Mayo Clin Proc 2005; 80: 1163-8.
36. Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10mg/d: a pilot study of the effects in hypercholesterolemic adultsunable to tolerate other statins and reach LDL cholesterol goalswith nonstatin lipid-lowering therapies. Clin Ther 2006; 28: 933-42.
37. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerabilityof fluvastatin XL 80 mg alone, ezetimibe alone, and the combinationof fluvastatin XL 80 mg with ezetimibe in patients with ahistory of muscle-related side effects with other statins. Am J Cardiol 2008; 101: 490-6.
38. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinicalpharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B.
39. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety ofatorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996; 60: 687-95.
40. Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potentinhibitor of HMG-CoA reductase, in healthy subjects. J ClinPharmacol 1996; 36: 728-31.
41. Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-weekrosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009; 103: 393-4.
42. Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008; 101: 1747-8.
43. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combinationwith twice a week Atorvastatin (10 mg) for statin intoleranthigh-risk patients. Am J Cardiol 2008; 101: 483-5.
44. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerabilityof every-other-day rosuvastatin dosing in patients with priorstatin intolerance. Ann Pharmacother 2008; 42: 341-6.
45. Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects ofonce weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007; 100: 554-5.
46. Dulay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternateday vs. daily dosing of rosuvastatin. Can J Cardiol 2009; 25: e28-e31.
47. Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other daycompared with once daily in patients with hypercholesterolemia. Ann Pharmacother 2006; 40: 1917-23.
48. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose ofatorvastatin effective in treating patients with hyperlipidemia? Thealternate day vs. daily dosing of atorvastatin study (ADDAS). AmHeart J 2002; 144: 674-7.
49. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses ofeffects on C-reactive protein and low density lipoprotein cholesterolin placebo-controlled trials of ezetimibe monotherapy orezetimibe added to baseline statin therapy. Am J Cardiol 2009;103: 369-74.
50. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterolassociatedactions of ezetimibe: an overview. Expert Opin TherTargets 2006; 10: 851-66.
51. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect ofezetimibe in patients who cannot tolerate statins or cannot get tothe low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
52. Venero CV, Venero JV, Seip RL, Thompson PD. Effectiveness ofthrice weekly ezetimibe. Am J Cardiol 2008; 102: 1205-6.
53. Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe inpatients with cardiovascular disease and statin intolerance or contraindications:a Markov model. Am J Cardiovasc Drugs 2008; 8:419-27.
54. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: isnow a good time to remember? Am J Ther 2007; 14: 567-80.
55. Clofibrate and niacin in coronary heart disease JAMA 1975; 231:360-81.
56. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelamhydrochloride in clinical practice: a new approach in thetreatment of hypercholesterolaemia. Curr Med Res Opin 2008; 24:995-1009.
57. Davidson MH. The use of colesevelam hydrochloride in the treatmentof dyslipidemia: a review. Expert Opin Pharmacother 2007;8: 2569-78.
58. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterolin patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31: 1479-84.
59. Tziomalos K, Athyros VG, Mikhailidis DP. Colesevelam improvesglycemic control and lipid management in inadequately controlledtype 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5:16-7.
60. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy andsafety of colesevelam in patients with type 2 diabetes mellitus andinadequate glycemic control receiving insulin-based therapy. ArchIntern Med 2008; 168: 1531-40.
61. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy andsafety of high-density lipoprotein cholesterol-increasing compounds:a meta-analysis of randomized controlled trials. J Am CollCardiol 2005; 45: 185-97.
62. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality inCoronary Drug Project patients: long-term benefit with niacin. JAm Coll Cardiol 1986; 8: 1245-55.
63. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant onnicotinic acid-induced flushing in patients with dyslipidemia. Am JCardiol 2008; 101: 625-30.
64. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: whathave we learned in the past 40 years? Pharmacotherapy 2007; 27:412-24.
65. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibratetherapy on cardiovascular events in 9795 people with type 2 diabetesmellitus (the FIELD study): randomised controlled trial. Lancet2005; 366: 1849-61.
66. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondaryprevention of coronary heart disease in men with low levels ofhigh-density lipoprotein cholesterol. Veterans affairs high-densitylipoprotein cholesterol intervention trial study group. N Engl J Med1999; 341: 410-8.
67. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primarypreventiontrial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidenceof coronary heart disease. N Engl J Med 1987; 317: 1237-45.
68. Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI. Comparison of the effects of plant sterol ester and plant stanolester-enriched margarines in lowering serum cholesterol concentrationsin hypercholesterolaemic subjects on a low-fat diet. Eur J ClinNutr 2000; 54: 715-25.
69. Nguyen TT, Dale LC, von BK, Croghan IT. Cholesterol-loweringeffect of stanol ester in a US population of mildly hypercholesterolemicmen and women: a randomized controlled trial. MayoClin Proc 1999; 74: 1198-206.
70. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination:therapy for hyperlipidemia: a review. Curr Med Res Opin2003; 19: 155-68.
71. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelamhydrochloride on low-density lipoprotein cholesterol and highsensitivityC-reactive protein when added to statins in patients withhypercholesterolemia. Am J Cardiol 2006; 97: 1198-205.
72. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combinationsimvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352-60.
73. Hunninghake D, Insull W, Jr., Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride withatorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158: 407-16.
74. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect ofezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
75. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibecoadministered with atorvastatin in 628 patients with primary hypercholesterolemia:a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
76. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministeredwith simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-34.
77. Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side-effect profile of combination ezetimibe andstatin therapy in randomized clinical trials. Am J Cardiol 2008;101: 1606-13.
78. Athyros VG, Tziomalos K, Mikhailidis DP, et al. Do we need astatin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007; 8: 2267-77.
79. McKenney JM, Jones PH, Bays HE, et al. Comparative effects onlipid levels of combination therapy with a statin and extendedreleaseniacin or ezetimibe vs. a statin alone (the COMPELLstudy). Atherosclerosis 2007; 192: 432-7.
80. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/ simvastatincoadministered with extended-release niacin in patients withtype IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51:1564-72.
81. Jelesoff NE, Ballantyne CM, Xydakis AM, Chiou P, Jones PH, Guyton JR. Effectiveness and tolerability of adding ezetimibe toniacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 2006; 12: 159-64.
82. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate forcombined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95: 462-8.
83. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate aloneand in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198-202.
84. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targetingvascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005; 54: 1065-74.
85. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorialtreatment on non-alcoholic fatty liver disease in metabolicsyndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-83.
86. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety ofthe coadministration of ezetimibe/simvastatin with fenofibrate inpatients with mixed hyperlipidemia. Am Heart J 2007; 153: 335-8.
87. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effectsof colesevelam HCl in combination with ezetimibe. Curr Med ResOpin 2006; 22: 2191-200.
88. Zema MJ. Colesevelam HCl and ezetimibe combination therapyprovides effective lipid-lowering in difficult-to-treat patients withhypercholesterolemia. Am J Ther 2005; 12: 306-10.
89. Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects ofcombined ezetimibe and colesevelam hydrochloride vs. ezetimibealone in hypercholesterolemic subjects: a pilot study. Metabolism2006; 55: 1697-703.
90. Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA. Colesevelamhydrochloride-ezetimibe combination lipid-lowering therapyin patients with diabetes or metabolic syndrome and a history ofstatin intolerance. Endocr Pract 2007; 13: 11-6.
91. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A. Efficacyand safety of coadministration of fenofibrate and ezetimibe comparedwith each as monotherapy in patients with type IIb dyslipidemiaand features of the metabolic syndrome: a prospective, randomized,double-blind, three-parallel arm, multicenter, comparativestudy. Am J Cardiovasc Drugs 2009; 9: 91-101.
92. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safetyof the coadministration of ezetimibe with fenofibrate in patientswith mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905.
93. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy oflong-term co-administration of fenofibrate and ezetimibe in patientswith mixed hyperlipidemia. J Am Coll Cardiol 2006; 47:1584-7.
94. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary arterydisease as a result of intensive lipid-lowering therapy in men withhigh levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
95. Carlson LA, Rosenhamer G. Reduction of mortality in the StockholmIschaemic Heart Disease Secondary Prevention Study bycombined treatment with clofibrate and nicotinic acid. Acta MedScand 1988; 223: 405-18.
96. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trialof a strategy for increasing high-density lipoprotein cholesterol levels:effects on progression of coronary heart disease and clinicalevents. Ann Intern Med 2005; 142: 95-104.
97. Bays H. Clinical overview of Omacor: a concentrated formulationof omega-3 polyunsaturated fatty acids. Am J Cardiol 2006; 98:71i-6i.
98. Robinson JG, Stone NJ. Antiatherosclerotic and antithromboticeffects of omega-3 fatty acids. Am J Cardiol 2006; 98: 39i-49i.
99. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Omega-3 fatty acids: how can they be used in secondary prevention? Curr Atheroscler Rep 2008; 10: 510-7.
100. Crane FL. Biochemical functions of coenzyme Q10. J Am CollNutr 2001; 20: 591-8.
101. Marcoff L, Thompson PD. The role of coenzyme Q10 in statinassociatedmyopathy: a systematic review. J Am Coll Cardiol 2007;49: 2231-7.
102. Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, andantioxidants in hypercholesterolemic men: a randomized controlledtrial. JAMA 2002; 287: 598-605.
103. Davidson M, McKenney J, Stein E, et al. Comparison of one-yearefficacy and safety of atorvastatin vs. lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997;79: 1475-81.
104. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatintreatment on natural antioxidants in low-density lipoproteinsand high-energy phosphates and ubiquinone in skeletal muscle. AmJ Cardiol 1996; 77: 851-4.
105. Paiva H, Thelen KM, Van CR, et al. High-dose statins and skeletalmuscle metabolism in humans: a randomized, controlled trial. ClinPharmacol Ther 2005; 78: 60-8.
106. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reducedlevels in muscle tissue during short-term simvastatin treatmentin humans. Clin Pharmacol Ther 1995; 57: 62-6.
107. Laaksonen R, Riihimaki A, Laitila J, Martensson K, Tikkanen MJ, Himberg JJ. Serum and muscle tissue ubiquinone levels in healthysubjects. J Lab Clin Med 1995; 125: 517-21.
108. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10level in statin-related myopathy. Arch Neurol 2005; 62: 1709-12.
109. Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10 preservesplasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin LabRes 1994; 24: 171-6.
110. Mabuchi H, Nohara A, Kobayashi J, et al. Effects of CoQ10 supplementationon plasma lipoprotein lipid, CoQ10 and liver andmuscle enzyme levels in hypercholesterolemic patients treated withatorvastatin: a randomized double-blind study. Atherosclerosis 2007; 195: e182-e189.
111. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzymeq10 on myopathic symptoms in patients treated with statins. Am JCardiol 2007; 99: 1409-12.
112. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatmentof statin adverse effects with supplemental Coenzyme Q10and statin drug discontinuation. Biofactors 2005; 25: 147-52.
113. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzymeQ(10) supplementation on simvastatin-induced myalgia. AmJ Cardiol 2007; 100: 1400-3.
114. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role ofcommon variants of ABCB1, CYP3A4, and CYP3A5 genes inlipid-lowering efficacy and safety of simvastatin treatment. ClinPharmacol Ther 2005; 78: 551-8.
115. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R,Gomez HJ. CYP2D6*4 polymorphism is associated with statininducedmuscle effects. Pharmacogenet Genom 2007; 17: 695-707.
116. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphismin the cytochrome CYP2D6 and the efficacy and tolerabilityof simvastatin. Clin Pharmacol Ther 2001; 70: 546-51.
117. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapydiscontinuation on mortality after myocardial infarction. ArchIntern Med 2006; 166: 1842-7.
118. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation:an underestimated risk? Curr Med Res Opin 2008 Sep 29 [Epubahead of print].
119. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardialinfarction: a population-based study. Eur Heart J 2008 Jul29 [Epub ahead of print].